Studies in two separate independent cohorts validated prostate cancer-associated transcript-14 (PCAT-14), an androgen-regulated lncRNA, might be used as a novel PCa diagnosis biomarker for its high expression prostate tumors and low expression linked to poor outcomes [21, 22]. The gene discussed is PCAT14; the disease is prostate neoplasm.